Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.
Lia Gore, MD
Advertisement
Lia Gore, MD, is section head of Pediatric Hematology/Oncology/BMT, the Ergen Family Chair in Pediatric Oncology, and co-director of the Developmental Therapeutics Program at the University of Colorado Cancer Center, as well as a member of the Colorado Children's Hospital.
Articles by Lia Gore, MD
Lia Gore, MD, and Sarah K. Tasian, MD, discuss key factors for the management of pediatric acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss the optimal timing of testing for KMT2A rearrangements in pediatric acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.
Lia Gore, MD, and Sarah K. Tasian, MD, discuss current treatment trends in pediatric relapsed/refractory acute leukemia.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5